Related Experiment Video
Updated: Apr 8, 2026
07:41
Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability
Published on: July 12, 2024
4.2K
Microneedles: an innovative platform for gene delivery
Joanne McCaffrey1, Ryan F Donnelly, Helen O McCarthy
1School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, UK, BT9 7BL, joanne.mccaffrey@qub.ac.uk.
Drug Delivery and Translational Research
|July 1, 2015
Summary
Microneedle technology offers a novel approach for gene therapy delivery, overcoming skin barriers to effectively deliver DNA for treating diseases and developing vaccines. This method enhances DNA therapeutics beyond traditional injections.
Area of Science:
- Biotechnology
- Gene Therapy Delivery Systems
Background:
- Gene therapy has advanced significantly over 20 years, moving from concept to a recognized treatment strategy.
- Limitations in current DNA delivery methods, beyond injections, hinder the full potential of gene therapy.
- Microneedle (MN) technology presents a promising alternative for therapeutic agent delivery.
Purpose of the Study:
- To review the advancements in microneedle-mediated DNA delivery.
- To examine the potential of MN technology for gene therapy and DNA vaccines.
- To identify key considerations for clinical application of MN DNA delivery.
Main Methods:
- Review of microneedle technology applications in DNA delivery.
- Analysis of MN-mediated delivery across skin barriers.
- Examination of DNA deposition in dermal layers for therapeutic targeting.
Main Results:
- Microneedle technology facilitates direct DNA delivery into dermal layers, bypassing skin barriers.
- The skin's immune-rich environment is suitable for DNA vaccine delivery via MNs.
- Progress has been made from proof-of-concept to delivering DNA for clinically relevant proteins and antigens.
Conclusions:
- Microneedle-mediated delivery is a viable platform for DNA therapeutics, especially for skin and cutaneous diseases.
- MN technology enhances gene delivery to target immune cells for vaccine development.
- Further technological improvements are crucial for the clinical translation of MN DNA delivery systems.
